GENOA, Italy — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain disorders, today announced that the first subject was treated with IAMA-6, an orally administered small molecule therapeutic targeting NKCC1. IAMA-6, IAMA’s lead program, is being evaluated for...
treatment News
SHANGHAI, NANJING, China and SAN JOSE, Calif. — IASO Biotechnology, a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercialising innovative cell therapy and antibody products, is pleased to announce that the Investigational New Drug (IND) application for its BCMA CAR-T (Equecabtagene Autoleucel) has been approved by the U.S. Food...
Ibrutinib improved event-free survival (EFS) when compared with placebo in patients with early-stage, asymptomatic chronic lymphocytic leukemia (CLL), according to phase 3 trial results published in Blood. However, because overall survival (OS) data from this trial are pending, researchers concluded that they cannot recommend ibrutinib over a “watch and wait” approach...
Daejeon, South Korea – The human brain’s adaptability to internal and external changes, known as neural plasticity, forms the foundation for understanding cognitive functions like memory and learning, as well as various neurological disorders. New research conducted by a team led by Dr. PARK Joo Min of the Center for...
LA JOLLA, Calif. – Innovative California Biosciences International, Inc., (“ICBII”), has announced the approval of its 7th patent for Blood-Brain Barrier (BBB) Permeable Peptide Compositions. Approval of this patent further strengthens Company’s IP portfolio of its SMART* Molecules technology and brings the management closer to the clinical trials. ICBII’s SMART molecules...
New York — Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific antibodies in oncology, announced the company has been granted orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA) for its first-in-class biparatopic 2+1 BEAT® bispecific antibody targeting CD38 and CD47 for the treatment...
The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Iclusig® (ponatinib; Takeda) for adults with chronic-phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to at least 2 prior kinase inhibitors. The sNDA approval is based on efficacy and safety data from the open-label...
SOUTH SAN FRANCISCO, Calif. — IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside the US and Canada) to evaluate IDE161,...
SOUTH SAN FRANCISCO, Calif. – IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced dose expansion of the ongoing Phase 1/2 study (ClinicalTrials.gov Identifier: NCT03947385) evaluating the combination of IDE196 and binimetinib in metastatic uveal melanoma (MUM). ...
Rio de Janeiro, Brazil – D’Or Institute for Research and Education (IDOR) played an important role in the phase III LIBRETTO-431 multicenter study, which evaluated the efficacy and safety of selpercatinib compared to control treatment, which consisted of platinum-based chemotherapy associated or not with pembrolizumab (immune checkpoint inhibitor) in non-small...